Аннотация:
Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine. Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95[%]) and HBeAg seroconversion (93[%] and 67[%], respectively). Cumulative rate of virologic resistance was 0; 3.1[%] and 43.5[%] for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, ð<0.0001) and reduction in the number of
Ключевые слова:
ALT normalization; Chronic hepatitis B; HBeAg seroconversion; HBsAg clearance; Nucleos(t)ide analogues; Safety; Virologic response
antivirus agent; entecavir; guanine; hepatitis B(e) antigen; nucleic acid synthesis inhibitor; telbivudine; tenofovir; analogs and derivatives; chronic hepatitis B; Hepatitis B virus; human; time factor; treatment outcome; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Telbivudine; Tenofovir; Time Factors; Treatment Outcome
Ибрагимов Э. К. Эльхан Кямранович 1989-
Абдурахманов Д. Т. Джамал Тинович 1967-
Розина Т. П. Тэона Павловна 1974-
Никулкина Е. Н.
Танасчук Е. Л.
Одинцов А. В. Алексей Владимирович 1964-
Паневкина С. В.
Моисеев С. В. Сергей Валентинович 1960-
Ibragimov E`. K. E`l`khan Kyamranovich 1989-
Abdurakhmanov D. T. Dzhamal Tinovich 1967-
Rozina T. P. Te`ona Pavlovna 1974-
Nikulkina E. N.
Tanaschuk E. L.
Odintsov A. V. Aleksej Vladimirovich 1964-
Panevkina S. V.
Moiseev S. V. Sergej Valentinovich 1960-
Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 91, Вып. 2 С. 40-47
2019
Статья
ALT normalization Chronic hepatitis B HBeAg seroconversion HBsAg clearance Nucleos(t)ide analogues Safety Virologic response
antivirus agent entecavir guanine hepatitis B(e) antigen nucleic acid synthesis inhibitor telbivudine tenofovir analogs and derivatives chronic hepatitis B Hepatitis B virus human time factor treatment outcome Antiviral Agents Guanine Hepatitis B e Antigens Hepatitis B virus Hepatitis B, Chronic Humans Nucleic Acid Synthesis Inhibitors Telbivudine Tenofovir Time Factors Treatment Outcome
Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine. Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95[%]) and HBeAg seroconversion (93[%] and 67[%], respectively). Cumulative rate of virologic resistance was 0; 3.1[%] and 43.5[%] for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, ð<0.0001) and reduction in the number of